Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

Haematologica

Volumn 96, Issue 12, 2011, Pages 1870-1873

  Thol, Felicitas ^a   Winschel, Claudia ^a   Lüdeking, Andrea ^a   Yun, Haiyang ^a   Friesen, Inna ^a   Damm, Frederik ^a   Wagner, Katharina ^a   Krauter, Jürgen ^a   Heuser, Michael ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

DNMT3A mutations; Mds occurrence

Indexed keywords

DEFERASIROX; DNA; DNA METHYLTRANSFERASE 3A; LENALIDOMIDE; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CODON; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); MUTATION RATE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK FACTOR; SOMATIC MUTATION;

ADOLESCENT; ADULT; COHORT STUDIES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 82855177869     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045559     Document Type: Article

References (16)

1. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009; 113(6):1315-25.
2. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605-13.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
4. Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet. 2009;41(11): 1207-15.
5. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-33.
6. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-8.
7. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95 (10):1668-74.
8. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29(18):2499-506.
9. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18(3):460-5.
10. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011;29 (3):303-9.
11. Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G, et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol. 1999;78(3):125-30.
12. Porter J. Oral iron chelators: prospects for future development. Eur J Haematol. 1989; 43(4):271-85.
13. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889-96.
14. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-15.
15. Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010;116(4):614-6.
16. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28(14):2356-64.